1623 Capital LLC Intellia Therapeutics, Inc. Transaction History

1623 Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	BUY	$58.27 - $118.99 $239,897 - $489,881	4,117 New	4,117 $299,000
Q4 2021 Feb 11, 2022	SELL	$100.76 - $138.36 $231,748 - $318,228	-2,300 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$132.37 - $176.78 $124,560 - $166,349	-941 Reduced 29.03%	2,300 $309,000
Q2 2021 Aug 13, 2021	SELL	$60.88 - $161.91 $13,819 - $36,753	-227 Reduced 6.55%	3,241 $525,000
Q1 2021 May 14, 2021	BUY	$46.59 - $83.68 $161,574 - $290,202	3,468 New	3,468 $278,000

336

96.1M

1.06M

863K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $699M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of 1623 Capital LLC, based on Form 13F filings with the SEC.

Stay updated on 1623 Capital LLC with notifications on news.